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The Ly49 receptors are type II C-type lectin-like membrane glycoproteins encoded by a
family of highly polymorphic and polygenic genes within the mouse natural killer (NK) gene
complex.This gene family is designatedKlra, and includes genes that encode both inhibitory
and activating Ly49 receptors in mice. Ly49 receptors recognize class I major histocompat-
ibility complex-I (MHC-I) and MHC-I-like proteins on normal as well as altered cells. Their
functional homologs in humans are the killer cell immunoglobulin-like receptors, which rec-
ognize HLA class I molecules as ligands. Classically, Ly49 receptors are described as being
expressed on both the developing and mature NK cells. The inhibitory Ly49 receptors are
involved in NK cell education, a process in which NK cells acquire function and tolerance
toward cells that express “self-MHC-I.” On the other hand, the activating Ly49 receptors
recognize altered cells expressing activating ligands. New evidence shows a broader Ly49
expression pattern on both innate and adaptive immune cells. Ly49 receptors have been
described on multiple NK cell subsets, such as uterine NK and memory NK cells, as well as
NKT cells, dendritic cells, plasmacytoid dendritic cells, macrophages, neutrophils, and cells
of the adaptive immune system, such as activated T cells and regulatory CD8+ T cells. In
this review, we discuss the expression pattern and proposed functions of Ly49 receptors
on various immune cells and their contribution to immunity.
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INTRODUCTION
Major histocompatibility complex (MHC) recognition is central
to both innate and adaptive immune recognition. The function
of both the innate immune effectors, such as natural killer (NK)
cells, and the adaptive immune effectors, such as T cells, depend
upon the recognition of MHC-I molecules expressed on aberrant
cells; however, the mode of recognition varies between the two
lymphocyte subsets. T cell receptors (TCR) have specificity to the
antigenic peptide bound to MHC-I and form contacts to the pep-
tide as well as to the MHC molecule (1, 2). NK cell receptors,
such as the Ly49 in mice, bind MHC-I molecules in a peptide-
dependent but not peptide-specific manner (3). An exception is
the Ly49C, a member of the Ly49 receptor family (Table 1), whose
binding to H-2Kb haplotype appears to be peptide-specific (3, 4).
The binding interface between Ly49 and MHC-I, revealed from
crystal structures of Ly49A and H-2Db molecules, is distinct and
away from the peptide binding groove on MHC-I (5). While signals
downstream of TCR engagement specifically activate T cell func-
tions, the Ly49 receptors can be activating or inhibitory in nature,
and their expression is not limited to NK cells. In addition to NK
cells, other leukocytes have also been shown to express inhibitory
Ly49 receptors, such as the CD8+ T cells, CD3+ cells, intestinal
epithelial lymphocytes (IELs), NKT cells, uterine NK cells (uNK)
cells, and cells of the myeloid lineage (6–12). Here, we review the
expression of Ly49 receptors on different cells of the innate and
adaptive immune system (Figure 1), and their contribution to
immunity.
Ly49 RECEPTORS
The innate MHC-I receptors include the human killer cell
immunoglobulin-like receptor (KIR), NKG2/CD94, and mouse
Ly49 families of receptors. The genes that encode the mouse MHC-
I receptors are clustered together in the natural killer gene complex
(NKC) on mouse chromosome 6. The Ly49 receptors are homod-
imeric type II glycoproteins of the C-type lectin-like superfamily.
They are structurally distinct but functionally similar to human
KIR in terms of MHC-I recognition, and therefore provide a use-
ful model system to study the role of this class of receptors in
immune regulation. A list of activating and inhibitory Ly49 recep-
tors in different mouse strains and KIR in humans is shown in
Table 1. MHC-I receptors generally inhibit NK cell function when
they are engaged by self-MHC ligands. Therefore, inhibitory Ly49
receptors are generally agreed to be important for the prevention
of autoimmunity by suppressing NK cell activation. The acquisi-
tion of inhibitory Ly49 for self-MHC-I is also a key step in the
“licensing” of developing NK cells to avoid a hyporesponsive state
(Figure 2A) (13). In contrast, the activating Ly49 receptors recog-
nize ligands that are expressed on abnormal or infected cells, and
activate cytokine production and cellular cytotoxicity by NK cells.
The integration of signals from the activating and inhibitory Ly49
receptors ultimately determines the functionality of NK cells.
INTRACELLULAR SIGNALING
The inhibitory and activating members of Ly49 and KIR families
are characterized by the presence or absence of immunoreceptor
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tyrosine-based inhibitory motif (ITIM) domains in their cyto-
plasmic tail (14–16). NK cell stimulation results in differen-
tial phosphorylation of Ly49 receptors. Mason and co-workers
first reported that tyrosine phosphorylation was restricted to
the inhibitory Ly49 molecules such as Ly49 A, C/I, and G2,
while the activating Ly49D was not phosphorylated (17). The
Table 1 | Mouse Ly49 and human KIR receptors for MHC-I.
Mousea Human Function
NOD 129 B6 BALB
Ly49D Ly49P Ly49D Ly49L KIR2DL4 Activating
Ly49H Ly49R Ly49H KIR2DS1
Ly49M Ly49U KIR2DS2
Ly49P1 KIR2DS3
Ly49P3 KIR2DS4
Ly49U KIR2DS5
Ly49W KIR3DS1
Ly49A Ly49Bb Ly49A Ly49A KIR2DL1 Inhibitory
Ly49Bb Ly49E Ly49Bb Ly49Bb KIR2DL2
Ly49C Ly49EC2 Ly49C Ly49C KIR2DL3
Ly49E Ly49G Ly49E Ly49E KIR2DL5
Ly49F Ly49I1 Ly49F Ly49G KIR3DL1
Ly49G2 Ly49O Ly49G Ly49I KIR3DL2
Ly49I Ly49Q1 Ly49I Ly49Q
Ly49Q Ly49S Ly49J
Ly49T Ly49Q
Ly49V
aLy49 pseudogenes do not encode any functional product and are not included.
bEncoded by a gene outside the Ly49 gene cluster.
phosphorylated Ly49 molecules were shown to be associated with
the src homology 2 (SH2) domain-containing protein phosphatase
SHP-1 in this study (17). Phosphorylation of the tyrosine residue
within the ITIM is responsible for the recruitment and activation
of SH2 domain-containing protein tyrosine phosphatases (18).
Although SHP-1 appears to be the major phosphatase required
for Ly49-mediated inhibition, it may not be the only inhibitory
mediator since Ly49A function is diminished but not completely
absent in mice deficient in SHP-1 (19). Although engagement of
inhibitory receptors results in ITIM phosphorylation, it is greatly
enhanced when it is cross-linked to an activating receptor com-
plex (20, 21). This demonstrates an elegant regulatory mechanism
whereby inhibitory receptor phosphorylation induced by engage-
ment of activating receptors results in recruitment of protein
tyrosine phosphatases, and the subsequent suppression of tyro-
sine phosphorylation-based signals downstream of the activating
receptors. In contrast to the inhibitory receptors, the activat-
ing Ly49 receptors transduce signals through associated adap-
tor proteins, such as DAP12, which possess an immunoreceptor
tyrosine-based activation motif (ITAM) (22–24). This interaction
is mediated by a charged residue (arginine) in the transmembrane
segment of Ly49, as was shown for Ly49D (25). Cross-linking
of activating Ly49 leads to phosphorylation of tyrosine residues
within the ITAM of DAP12 as well as phosphorylation of other
proteins, including members of the Src-family of tyrosine kinases,
the mediators of downstream signaling events (26).
GENETIC DIVERSITY
One of the striking features of Ly49 receptors is the polymorphic
and polygenic nature of the Ly49 gene cluster among the inbred
mouse strains (27–30). This results in heterogeneity in both the
type and level of Ly49 molecules expressed in different mouse
strains (Table 1) (31). Among the four inbred mouse strains whose
Ly49 gene haplotypes have been extensively characterized, the
FIGURE 1 | Schematic representation of cell types expressing
Ly49 receptors. Receptor repertoire and proposed functions of Ly49
in different cellular subsets is shown based on literature reports in
C57BL/6 mice. NK, natural killer; uNK, uterine natural killer; NKT,
natural killer T; DC, dendritic cells; pDC, plasmacytoid dendritic cell;
α-GalCer, α-galactosylceramide; VEGF-A, vascular endothelial growth
factor A; TLR, Toll-like receptor; IFN-I, type I interferon; n.d., not
determined.
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FIGURE 2 | Schematic representation of the role of Ly49 receptors in
NK cell development and function. (A) During NK cell development,
interactions between the inhibitory Ly49 receptors and their self-MHC-I
ligands on normal cells result in NK cell functional maturation
(education/licensing). (B) Licensed Ly49+ but not unlicensed Ly49− NK cells
recognize MHC-I-deficient cells and kill them through the release of lytic
granules (missing-self recognition). (C)Tumor cells express ligands which
are recognized by activating receptors on NK cells. However,
MHC-I-expressing tumor cells can inhibit licensed NK cells through
interactions with their inhibitory Ly49 receptors. Unlicensed NK cells will
not be inhibited in this way because they lack Ly49 receptors.
BALB/c mouse strain possess the smallest haplotype with 8 genes
(32), and the NOD/ShiLtJ strain possess the largest haplotype with
21 discernable genes (33). The C57BL/6 haplotype, which was
the first to be characterized, and the 129 mouse strain haplotype
possess 15 and 19 genes, respectively (28, 29, 34–36). In all the char-
acterized Ly49 haplotypes, there appears to be a limited degree of
conservation in the form of “framework”genes which delineate the
regions of variable numbers of strain-specific genes. The frame-
work gene pairs in mice are Ly49q-e, Ly49i-g, and Ly49c-a. Ly49
haplotype diversity has evolved as a result of multiple duplication
and deletion events. Examples of strain-specific Ly49 gene inacti-
vation are evident in different strain of mice mostly mediated by
stop codons within the coding region (37–39). Such diversity is
possibly driven by selective pressure due to pathogenic challenge,
since NK cells appear to be critical for the control of viral infections
(40, 41). In mice, the activating Ly49H receptor directly interacts
with the murine cytomegalovirus (MCMV) m157 gene product on
NK cells and confers resistance to MCMV in the C57BL/6 mouse
FIGURE 3 | Schematic representation of the role of the activating
Ly49H receptors in recognition of MCMV-infected cells. NK cells from
C57BL/6 but not 129 or BALB/c mouse strains express Ly49H and are
capable of recognizing m157 viral protein on the surface of MCMV-infected
cells, thereby, conferring resistance against MCMV infection.
strain which possesses the Ly49h gene (Figure 3). Conversely, 129
and BALB/c strains lack the gene for activating Ly49H and hence
are highly susceptible to MCMV infection (42–47).
Ly49 EXPRESSION AND FUNCTION ON NK CELLS
Ly49 receptors are best known for their role in the regulation of NK
cell functions. Both the activating and inhibitory Ly49 receptors
are expressed by NK cells (Figure 1). Murine NK cells express up to
six members of the Ly49 receptor family in an overlapping fashion,
such that the average NK cell expresses two to three Ly49 receptors
(48). Ly49 expression begins early during NK cell development in
the bone marrow (BM). An in vivo differentiation study demon-
strated that there are five stages of NK cell development in murine
BM, as assessed by surface expression of NK cell markers (49). In
the first three stages of development, NK cells sequentially attain
expression of CD122 (stage I; CD122+ NK1.1− DX5− Ly49−),
then NK1.1, DX5, and NKG2A (stage II; CD122+ NK1.1+ DX5lo
CD94/NKG2A+ Ly49−), and finally Ly49 at stage III. Afterward,
immature NK cells undergo extensive cell division and expansion
in stage IV followed by functional maturation at stage V of their
development (49). Ly49E is the only member of Ly49 family that
is expressed on fetal NK cells and its expression is lost early after
birth (50). Expression of other Ly49 family members are detected
on developing NK cells during the first 2–3 weeks after birth and
reach optimal levels within 6–8 weeks after birth (50, 51).
NK CELL EDUCATION AND TARGET CELL RECOGNITION
Ly49 receptors play an important role in NK cell education and
recognition of target cells. The mechanism behind NK cell recog-
nition of target cells was discovered by Kärre and colleagues, and
accordingly named the“missing-self hypothesis”(Figure 2B) (52).
According to the hypothesis, NK cells survey MHC-I expression on
cells with which they come into contact (52). Abnormal or infected
cells often down-regulate expression of MHC-I on their surface in
order to avoid detection and killing by cytotoxic T cells; however,
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this down-regulation is recognized by, and functions as a kill signal
for NK cells (52). In this seminal work, the RBL-5 lymphoma cell
line was mutagenized to derive two new cell lineages, an MHC-
I-expressing RMA and MHC-I-deficient RMA-S. It was observed
that the MHC-I-deficient RMA-S cells, following injection into
mice, were rapidly eliminated while the MHC-I-expressing RMA
cells were able to develop into tumors (52). This “missing-self”
hypothesis was further supported by the finding that cells isolated
from mice lacking expression of β2m, the light chain component
of MHC-I that is necessary for its surface expression, were read-
ily recognized and killed by NK cells, while re-introduction of
a β2m transgene restored the resistance to NK cell killing (53).
In addition to the increased susceptibility of cells isolated from
MHC-I-deficient mice to NK cell killing, it was also noted that
NK cells from β2m−/− mice exhibited a diminished ability to kill
traditional NK cell targets, when compared to wild-type (WT)
mice (53). This led to the proposal that MHC-I interactions dur-
ing NK cell development are needed for induction of NK cytolytic
activity (Figure 2A). This hypothesis was later substantiated by
the discovery that NK cells must undergo an MHC-I-dependent
“licensing” process in order to be functional, in which a self-
specific Ly49 receptor interacts with self-MHC-I (13). Similarly,
we have demonstrated that the NK cells from Ly49-deficient mice
are unlicensed and show impaired missing-self response against
MHC-I-deficient target cells (54). This education requirement has
also been found in human NK cells with the interaction of MHC-
I and KIR (55, 56). The licensed NK cells are functionally active
while at the same time self-tolerant due to recognition of MHC-I
through their inhibitory Ly49 receptors. In contrast, the unlicensed
NK cells – which lack self-MHC-specific inhibitory receptors – are
tolerant due to their hyporesponsive nature.
The mechanics of the education process are still unknown,
with various contested models. While education was originally
thought to occur during NK cell development in the BM (13),
adoptive transfer studies utilizing splenic NK cells from MHC-I
deficient mice into WT hosts were able to restore NK function-
ality, thus showing that education does not occur only during
development of immature NK cells, but is actually a dynamic and
reversible process (57, 58). The arming and disarming model are
the most widely accepted models thus far. Based on the arming
model, NK cells which lack expression of an inhibitory self-MHC-
I-specific Ly49 receptor are unable to fully mature into functional
NK cells (become “armed”) and thus remain in their hyporespon-
sive state (59). In contrast, the disarming model proposes that NK
cells which lack expression of an inhibitory self-MHC-I-specific
Ly49 receptor, and thus are chronically stimulated due to lack of
inhibitory signaling, become anergic and hyporesponsive to target
cells (59).
The type of interaction between the Ly49 receptor and the
MHC-I molecule during education has also been shown to be
important and somewhat controversial: it is unknown whether
the Ly49 is interacting in cis with MHC-I on the NK cell surface
itself or in trans with the MHC-I expressed on another cell. Trans-
mediated licensing is supported by various groups, using either
adoptive transfer from MHC-I-deficient mice in WT recipients
or doxycycline-inducible MHC-I expression in MHC-I-deficient
β2m−/− mice to observe interactions between MHC-I-deficient
NK cells in an MHC-I-sufficient environment (57, 58, 60). On
the other hand, using a modified Ly49A receptor, which is only
capable of binding in trans with ligands on other cell surfaces but
not in cis, Chalifour and colleagues found that NK cells from these
mice did not appear to be fully educated (61). As well, Bessoles and
colleagues’ recent work also suggests a cis interaction contribution
to NK functionality, though the precise role is not clear (62).
NK CELL-MEDIATED IMMUNOSURVEILLANCE
Major histocompatibility complex-I-dependent “missing-self”
recognition by NK cells has great implications on the immuno-
surveillance of abnormal cells which have lost surface expression
of MHC-I molecules. Lost or aberrant surface expression of MHC-
I in human tumors is classified into seven phenotypes as follows:
(1) total HLA loss, (2) HLA haplotype loss, (3) HLA locus loss, (4)
HLA allelic loss, (5) compound phenotypes, (6) unresponsiveness
to interferons (IFNs), and (7) gain of MHC-Ib (63). Altered MHC-
I expression is highly prevalent in human tumors and various alter-
ations have been associated with different cancer types: HLA hap-
lotype loss is the most common alteration and has been described
in laryngeal (64), non-Hodgkin’s lymphoma (65), and pancreatic
cancer (66). Loss of MHC-I expression along with up-regulation
of ligands for activating NK cell receptors on tumor cells results in
their recognition and elimination by NK cells. We have shown that
Ly49-deficient mice are unable to recognize and eliminate MHC-
I-deficient target cells (54). On the other hand, the 5E6 antibody
(to block the inhibitory Ly49I/C signaling) and 1-7F9 antibody (to
block KIR signaling) have been shown to be useful in the treatment
of leukemia and multiple myeloma in mice and humans, respec-
tively; therefore, manipulation of human KIR signaling has been
proposed as a potential cancer therapeutic (67–70). Finally, there
is also evidence that a member of the Ly49 receptor family, Ly49A,
recognizes the non-classical MHC-I molecule H2-M3 and in part
mediates NK cell licensing (71). Ly49A+ NK cells from WT mice
exhibit enhanced responsiveness compared to H2-M3-deficient
mice. H2-M3-deficient mice display defective tumor control with
increased B16F10 pulmonary metastatic burden, and increased
incidence of MCA-induced fibrosarcoma (71, 72).
More recently, a paradigm shift was suggested following the
study by Tarek and colleagues, wherein it was found that unli-
censed NK cells are better at killing neuroblastoma tumors (73).
Unlike the traditionally low levels of MHC-I expression on tumors,
neuroblastoma cells express high levels of MHC-I, which can
inhibit licensed NK cells. On the other hand, the unlicensed
NK cells are not inhibited by MHC-I on neuroblastoma cells
(Figure 2C). It was found that patients lacking HLA ligands for
their KIRs showed improved prognosis and survival when treated
with 3F8, an antibody targeting the disialoganglioside surface anti-
gen, in contrast to the educated NK cells which were selectively
inhibited by HLA ligands expressed on the tumor cells (73). In such
case, the inhibitory signals through KIR-dependent recognition of
HLA on the target cell dampen the beneficial effect of educated
NK cells. Blocking this KIR interaction with MHC-I could prove
therapeutically beneficial in such circumstances.
The Ly49 receptors on NK cells also play a role in immunity
against virus infections. The importance of NK cells in innate
defense against viral infections was highlighted by studies which
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have shown severe and recurrent infections by otherwise benign
viruses in individuals lacking NK cell functions (40, 41). Viruses
have developed several strategies to evade recognition of NK cells.
This may occur by expression of viral proteins on infected cells
that resemble host MHC-I molecules and inhibit NK cells through
interaction with the inhibitory receptors, or by down-regulation
of activating ligands on the surface of infected cells (74). The
arms race between the viruses and NK cells has resulted in the
selection of receptors for their ability to specifically recognize
virus-infected cells. For instance, the activating Ly49H receptor
on NK cells has evolved to recognize the glycoprotein m157, a
MCMV-encoded structural homolog of MHC-I, on the surface
of infected cells and imparts resistance in the C57BL/6 mouse
strain (Figure 3) (46). Ly49H-deficient C57BL/6 mice and other
mouse strains (129 and BALB/c), which lack the gene encoding
for Ly49H, are highly susceptible to MCMV infection (43, 46,
47). The mutant MCMV strain that lacks m157 glycoprotein is
significantly more virulent in C57BL/6 mice (75), indicating an
important role for Ly49H in host defense against MCMV. Similarly,
the activating Ly49P receptor protects MA/My mice from lethal
MCMV infection through the recognition of MCMV-encoded
m04 proteins in association with H-2Dk MHC-I haplotype (76).
Mutant MCMV strains that lack m04 are lethal in MA/My mice
since this mouse also lacks the activating Ly49H (77). Interest-
ingly, Orr and colleagues have demonstrated that Ly49H+NK cells
that do not express inhibitory Ly49 receptors are more efficient in
controlling MCMV infection than Ly49H+ NK cells that express
inhibitory Ly49 receptors, possibly due to the lack of inhibitory
signals in the former (78). Therefore, blocking inhibitory recep-
tors on NK cells may have beneficial therapeutic effects in certain
viral infections, as has been shown in cancers of humans and mice
(67–70).
Ly49 EXPRESSION AND FUNCTION ON UTERINE NK CELLS
Uterine NK cells (uNK) are resident lymphocytes of the uterus.
In the non-pregnant mouse uterus, uNK cells are few and express
CD122, CD49b (DX5), NKp46, CD11b, CD27, and CD69; a phe-
notype similar to peripheral blood and spleen NK cells (11, 79).
These cells also express Ly49G2 (80, 81). During pregnancy, a mas-
sive influx of NK cells expressing Ly49 receptors occurs in the
mouse decidualized uterus (11, 82–84). In the decidua, two subsets
of uNK cells are identified based on the expression of N -acetyl-
d-galactosamine, which can bind the Dolichos biflorus agglutinin
(DBA) lectin: DBA+ and DBA− subsets (11, 83). Both subsets
are known to express Ly49 receptors (Figure 1) (11). DBA− uNK
cells originate from NK progenitors cells (Lin−CD122+NK1.1−)
and like splenic NK cells, they are the source of decidual IFN-γ.
However, their frequency remains constant throughout the preg-
nancy (11, 84, 85). DBA+ uNK cells are absent in the non-pregnant
uterus, expand dramatically up to mid-gestation (gestational day
8.5–10.5), and decrease again in late pregnancy (11, 83, 86). The
DBA+ uNK cells have a unique receptor repertoire which includes
Ly49 receptors (11). Early in pregnancy, they perform potent
vasculo-angiogenic activity demonstrating that they are active NK
cells (85–90). The origin of DBA+ uNK cells is unclear, but uterus
transplant experiments suggest that DBA+ uNK cells are recruited
from the circulation (91).
The Ly49 receptor repertoires of DBA+ and DBA− uNK cells
differ. Ly49C/I and D are expressed at low levels and Ly49G2 is
highly expressed on DBA+ compared to the DBA− uNK cells,
while Ly49A and H are expressed at similar levels (11). They seem
to play an important role during mouse pregnancy. Antigenic dis-
parity between parental H-2K genes (BALB/C: d haplotype and
B6: b haplotype) affects the trophoblast-induced transformation of
uterine vasculature (92). In the B6 mouse strain, the trophoblast
giant cells express high levels of H-2Kb and H-2Db, the ligands
for various Ly49 receptors (92–94). Our observation of preg-
nancy defects in the Ly49-knockdown mouse model and the works
described above, suggest an important role of Ly49 receptors on
uNK cells in mouse pregnancy.
In addition to their role in normal pregnancy, uNK cells can
act as effector cells against infectious agents at the maternal–fetal
interface. Human cytomegalovirus (HCMV) is the most com-
mon cause of intra-uterine and congenital virus infection (95).
Human uNK cells have been shown to display cytotoxic effector
function upon recognition of HCMV-infected cells (96). Dur-
ing mouse pregnancy, MCMV infection results in vascular dys-
function of mesenteric and uterine arteries (97). The activating
Ly49H receptor is responsible for recognition and elimination of
MCMV-infected cells (46). In addition, uNK cells express several
vaso-active factors to regulate vaso-constriction and dilation (98),
thereby making them potential modulators during normal and
infectious pregnancy complications.
Ly49 EXPRESSION AND FUNCTION ON NKT CELLS
NKT cells are defined as CD1d-restricted T cells that express an
invariant T cell antigen receptor, variable (V) and joining (J)
Vα14Jα18 in mice, and Vα24Jα18 in humans, combined with a
limited TCRβ chain repertoire (Vβ8.2, Vβ7, or Vβ2 in mice and
Vβ11 in humans). These TCR αβ-chain combinations result in
NKT cells with specificity for glycolipid antigens presented by the
MHC-I-related CD1d surface protein (99, 100).
Murine TCRαβ+ NK1.1+ NKT cells are known to express
other NK cell-associated molecules including CD122, CD16, DX5,
CD94/NKG2, and the Ly49 family of receptors. Thus far, only
inhibitory Ly49 receptors have been shown to be expressed on
NKT cells (Figure 1) (101). One reason for this could be that,
forced expression of Ly49D, an activating receptor, on T cells by
transgenesis results in impaired thymocyte maturation (102). It
has been shown that Ly49 expression inversely correlates with their
response to α-galactosylceramide (α-GalCer), a potent stimula-
tor of CD1d-restricted NKT cells. MHC-I-dependent α-GalCer
presentation by dendritic cells (DC) stimulates Ly49− but not
Ly49+ NKT cells (12). On the other hand, MHC-I-deficient DCs
effectively present α-GalCer to Ly49+ splenic NKT cells. When
Ly49:MHC-I interactions are blocked using anti-Ly49 A, C/I, and
G monoclonal antibodies (mAb), Ly49+ NKT cells were efficiently
stimulated with α-GalCer-pulsed DCs, demonstrating inhibition
of TCR-mediated activation signals by inhibitory Ly49:MHC-I
interactions on NKT cells (101). Therefore, Ly49 receptors appear
to have a similar role in regulating NKT cell responses as has been
described for NK cells.
Expression of Ly49 and response to α-GalCer vary greatly
among NKT cells from different anatomical sites. Almost 85%
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of splenic CD1d-independent NKT cells from β2m-deficient mice
express Ly49A, C, G, or I, whereas only 50% of splenic NKT cells
from WT mice express these Ly49 receptors (12). In the mouse
thymus, over 75% of NKT cells stain with CD1d tetramers (103).
Similarly, Oberg and colleagues have reported that almost 70%
of thymic NKT cells express Ly49A, C, G, or I (12). Despite the
high percentage of CD1d-restricted NKT cells in the thymus,
thymic NKT cells are weakly stimulated with α-GalCer-pulsed
DCs as compared with splenic NKT cells. The inability of most
thymic NKT cells to respond to α-GalCer does not seem to be
due to inhibition via Ly49:MHC-I interaction, because α-GalCer-
pulsed MHC-I-deficient DCs also fail to stimulate thymic NKT
cells (104). It seems likely that CD1d-restricted Ly49+ thymic
NKT cells may be functionally immature and may constitute
the precursors for mature CD1d-restricted NKT cells. Whereas
thymic NKT cells are thought to be precursors of splenic CD1d-
restricted NKT cells, the origin of NKT cells in BM is still unclear.
Phenotypically, they are different from thymic NKT cells (105),
and are thought to be extra-thymically derived (106). Almost
85% of BM NKT cells express Ly49A, C, G, or I, however, only
30% of them bind CD1d tetramers (103). Like their thymic
counterparts, BM NKT cells do not respond to α-GalCer-pulsed
MHC-I-sufficient and -deficient DCs. It remains to be determined
whether all CD1d-restricted BM NKT cells are Ly49+, and whether
they are immature NKT cells belonging to a separate NKT cell
lineage.
Ly49 EXPRESSION AND FUNCTION ON CELLS OF THE
MYELOID LINEAGE
While most members of Ly49 family of receptors are exclusively
expressed on NK, NKT, and T cell subsets, Ly49Q and B have a
unique pattern of expression and are found on distinct subsets
of myeloid lineage cells (6, 8, 107). Ly49B is expressed on mul-
tiple distinct subpopulations of myeloid cells defined by CD11b
and Gr-1 expression, with morphological characteristics of gran-
ulocytes and monocyte/macrophages (8). Ly49B expression was
generally low in these cells and was up-regulated when cells were
treated with lipopolysaccharide (LPS), IFN-α, and IFN-γ. Cells
expressing Ly49B were reported to be more numerous in the
Peyer’s patches and the lamina propria of the gut, implicating
a role of Ly49B in gut immunobiology (8). Interestingly, Ly49B
and Q were reported to be expressed on non-overlapping myeloid
subpopulations among freshly isolated spleen and BM cells (8).
Ly49Q is an inhibitory receptor and has been shown to asso-
ciate with SHP-1/2 upon cross-linking (107). Its expression was
detected on Gr-1+ cells in mouse fetal liver and adult BM and
spleen. Expression was found to be higher on immature myeloid
precursors and IFN-γ-treated macrophages (107). Ly49Q cross-
linking on macrophage cell lines induces formation of cell polarity
and spreading through cell cytoskeletal rearrangement (Figure 1)
(107). Similarly, Ly49Q appears to be essential for cellular polar-
ization and invasion of extravascular tissues by neutrophils during
an inflammatory response (Figure 1) (108). In addition, Ly49Q
expression is induced on osteoclasts which differentiate from
the monocyte/macrophage lineage cells by receptor activator of
nuclear factor-κB ligand (RANKL) treatment, and plays a role in
osteoclastogenesis (109).
Another myeloid lineage cell type that expresses high levels
of Ly49Q is the plasmacytoid dendritic cell (pDC) (Figure 1).
Virtually all peripheral and the majority of BM pDCs express
Ly49Q, which also correlates with the sequential development
and activation of these cells (6, 7, 110). pDCs are specialized
in direct virus recognition and secretion of large amounts of
IFN-I early during infection (111, 112). Using a gene knock-
out mouse model, we have shown that Ly49Q, despite being an
inhibitory receptor, positively regulates Toll-like receptor (TLR)-
mediated IFN-I production by pDCs (113, 114). In mice lack-
ing Ly49Q, both TLR7 and TLR9-mediated IFN-I production
by pDCs is attenuated (113). Although the precise mechanism
of this positive regulation is not known, it is Ly49Q ITIM-
dependent but may not involve interaction with the SHP-1/2
phosphatases (114). One of the possible mechanisms could be
a cooperative activation of interferon regulatory factors (IRF)
in conjunction with TLR-mediated downstream signals, lead-
ing to enhanced IFN-I production. Alternatively, Ly49Q may aid
in the uptake of microbial macromolecules, such as unmethy-
lated CpG oligodeoxynucleotides (ODN), and their trafficking
to endosomal compartments where TLRs are located. We have
demonstrated a specific down-regulation of Ly49Q from the
pDC surface when treated with TLR9 agonist CpG ODN (114).
This is similar to the down-regulation and co-internalization of
human KIR3DL2 with CpG ODN in NK cells (115). A direct
in vitro binding of CpG ODN to KIR3DL2 was also shown
in this study. Co-localization of Ly49Q with CpG ODN in
TLR9 containing endosome/lysosome compartments has previ-
ously been demonstrated, however it remains to be determined
if Ly49Q is the sensor and distributor of CpG ODN to these
compartments (116).
Ly49 EXPRESSION AND FUNCTION ON CD8+ T CELL SUBSETS
Although Ly49 receptors are best known as innate immune recep-
tors, their expression is not limited to the cells of the innate
immune system which we have discussed above (Figure 1). Here,
we will shift our attention to the Ly49-expressing T cells from the
CD8 lineage, cells of the adaptive immune system. This popula-
tion, along with the analogous KIR-expressing CD8+ T cells in
humans, has only recently garnered much attention.
CD8αα+ INTESTINAL INTRAEPITHELIAL LYMPHOCYTES (IEL)
Ly49-expressing CD8+ T cells can be further classified based on
whether they express a CD8αα or CD8αβ co-receptor. T cells
expressing CD8αα and Ly49 receptors were identified among the
IELs (10). Microarray analysis, confirmed by flow cytometry, com-
paring these cells to traditional intestinal CD8αβ T cells showed
a marked increase in surface Ly49 expression, with CD8αα IELs
possessing an Ly49 repertoire similar to – but distinct from – the
NKT cells discussed above. Notably, although these IELs, like NKT
cells, express predominantly inhibitory Ly49 receptors, the CD8αα
T cells have also been shown to up-regulate Ly49D and H mRNA
levels and display an increase in the activating DAP12 adaptor
molecule, suggesting they may have some degree of activating Ly49
expression (10). Also, their Ly49 expression profile is remarkable
based on its high levels of Ly49E and F, both of which are very rare
in NK cell populations. Indeed, the bulk of CD8αα IELs are Ly49E
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and/or F positive, with the proportion of Ly49E/F double-positive
cells roughly corresponding to the product of the proportions of
single-positive cells (10). What role these cells may play in gut
homeostasis is still unclear, although one report suggests that a
subset of Ly49-expressing CD8αα IELs recognize the non-classical
MHC-I molecule Qa-1 (HLA-E in humans) through their TCR
and play an immune-regulatory role (117).
CD8αβ+ T CELLS
In both humans and mice, the CD8αβ Ly49-expressing cells
are mainly found among the CD122-expressing, memory-
phenotype CD8+ T cells: CD25−Ly6C+CD44+ in mice, and
CD28−CD45RA−CD45R0+ in humans (118). Despite being
memory-phenotype and expanding with the age of the animal,
these cells are present from an early age, suggesting that they are
not true memory cells but a naturally occurring subpopulation
of CD8+ T cells (119). As with NKT cells, they appear to express
only inhibitory NK receptors. Additionally, like the CD8αα IELs,
these CD8αβ T cells have non-NK-like Ly49 repertoires, in this
case dominated by Ly49F expression in B6 mice (119).
Attempts to discern the purpose of inhibitory Ly49 or KIR
expression on these cells have thus far identified two non-exclusive
candidate functions. First, and most intuitive, expression and
subsequent engagement of an inhibitory MHC-I receptor down-
regulates killing activities from the T cell. Transgenic expression of
the inhibitory Ly49A or KIR2DL3 on T cells inhibits their ability
to kill MHC-mismatched target cells, provided that those targets
express a ligand for the inhibitory NK receptor (120, 121). As this
role for Ly49 or KIR expression is shared between T and NK cells,
it is probable that it is for the same purpose: both CD8+ T cells and
NK cells are directly lytic to self-cells while mounting an anti-viral
or anti-tumor response, and so must have a method for healthy
cells to be recognized and spared to avoid rampant autoimmu-
nity (120). Especially in the case of regulatory T cells (discussed
further below), Ly49 expression may allow for a population of
CD8+ T cells with highly self-reactive TCRs that are regulated by
inhibitory Ly49 receptors, analogous to NK immune surveillance.
Such a model also suggests that T cells express only inhibitory Ly49
receptors because their TCR expression is performing a similar role
as the activating receptor on the NK cell.
Interestingly, however, these inhibitory NK receptors appear to
have a second function on T cells, conferring enhanced expan-
sion and survival to the Ly49 or KIR positive cell. Although to date
there is no study directly showing that Ly49 expression on mouse T
cells confers enhanced IL-15 sensitivity, there are lines of evidence
to suggest this. First, there is a marked correlation between Ly49
expression and IL-15 sensitivity on mouse CD8+ T cells (122).
Using a simple CFSE proliferation assay, this report showed that,
although many CD122-expressing T cells are IL-15 sensitive, those
that also expressed Ly49 expanded most vigorously after IL-15
stimulation. Second, transgenic expression of a KIR on murine T
cells causes those T cells, but not WT or KIR-expressing B cells,
to possess a marked proliferation advantage when transferred into
mice transgenic for the KIR ligand, but not when transferred into
WT mice (118). Taken together, these reports strongly suggest that
although Ly49/KIR expression may reduce a T cell’s cytotoxicity,
it also enhances that cell’s longevity.
CD8+ T CELLS WITH REGULATORY FUNCTIONS
Such a paradigm, where Ly49+ T cells are long-lived, broadly
active, and/or highly self-reactive cells regulated by inhibitory Ly49
receptors, agrees conceptually with recent work from the Cantor
lab and others demonstrating that Ly49-expressing CD8αβ + T
cells include or entirely comprise a regulatory population impli-
cated in preventing or controlling such autoimmune diseases as
systemic lupus erythematosus (SLE), multiple sclerosis (MS), and
rheumatoid arthritis (RA) (123–125). Much like the proposed
regulatory CD8αα T cells above, these CD8αβ+ Treg cells are char-
acterized by a TCR restricted to the non-classical MHC molecule
Qa-1 (HLA-E in humans) and reacting to a peptide derived from
the HSP60 leader sequence (126). They act as indirect regulators
of antibody production, by targeting the Qa-1-expressing follicu-
lar helper T cells (TFH) and lysing them in a perforin-dependent
manner (127). Employing a strategy not unlike the NK cell use
of inhibitory and activating Ly49, these CD8+ Treg cells express
NKG2A, an inhibitory NK receptor that recognizes Qa-1 present-
ing its dominant peptide, Qdm, which normally prevents their
killing of TFH cells. However, in cases of overactive TFH giving rise
to excessive antibody production by plasma cells, a shift toward
more HSP60sp being presented by Qa-1, allows the CD8 Treg cell’s
TCR to compete with NKG2A and transmit an activating signal
to the CD8+ Treg cell. In a recent report, it was found that dis-
rupting the ability for Qa-1 to interact with the CD8+ Treg cell’s
TCR – but not disrupting the NKG2A interaction – caused a mas-
sive expansion in TFH and plasma cell numbers, splenic germinal
center area, and serum and kidney antibody deposition, analo-
gous to that seen in SLE-susceptible mice (127). Furthermore,
adoptive transfer of these CD8+ Treg cells into Rag−/−mice with a
reconstituted CD4+CD25− T cell and IgM+ B cell compartment
results in a suppression of antibody production upon immuniza-
tion with NP, which appears to be mediated by the Ly49+, but not
Ly49− CD8+ Treg cells (127). While no studies have yet shown
a direct role for Ly49 in this regulation, the dual functions dis-
cussed above fit well with this model of regulation. On the one
hand, the longevity and antigen-independent, IL-15-driven acti-
vation and proliferation of these T cells allows for their continuous
presence and immunosurveillance within the organism in ques-
tion; at the same time, the limiting effect of Ly49 and NKG2A,
coupled with the scarcity of this CD8+ Treg population, ensures
that enough antibody is allowed to be produced to protect the host
from infection.
CONCLUSION
Members of the Ly49 family of receptors, like the human KIR,
have a broader expression pattern than previously thought. Their
expression is not restricted to NK and other cells of the innate
immune system, but also found on cells of adaptive immune
system. Similarly, their function seems to be broad and vary
from regulation of target recognition by NK and possibly NKT
cells, regulation of uNK cell functions during pregnancy, sens-
ing of microbial macromolecules and stimulation of cytokine
production by pDC, and modulation of autoimmune diseases
by affecting survival and function of Ly49-expressing CD8+ T
cells. The Ly49:MHC-I interactions are amenable to modulations
with potential therapeutic agents, and the recent developments in
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understanding MHC-I receptor expression and function will aid
in better design of such strategies.
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